ES2174109T3 - Composicion antibacteriana para administracion oral. - Google Patents

Composicion antibacteriana para administracion oral.

Info

Publication number
ES2174109T3
ES2174109T3 ES96933635T ES96933635T ES2174109T3 ES 2174109 T3 ES2174109 T3 ES 2174109T3 ES 96933635 T ES96933635 T ES 96933635T ES 96933635 T ES96933635 T ES 96933635T ES 2174109 T3 ES2174109 T3 ES 2174109T3
Authority
ES
Spain
Prior art keywords
composition
cefditoren
pivoxyl
oral administration
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96933635T
Other languages
English (en)
Inventor
Kenichi Abe
Masato Ota
Hiroyuki Yamaguchi
Chikako Murakami
Toshihiro Kikkoji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Application granted granted Critical
Publication of ES2174109T3 publication Critical patent/ES2174109T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE PRESENTA UNA NUEVA COMPOSICION ANTIBACTERIANA PARA ADMINISTRACION ORAL, QUE CONTIENE UNA MEZCLA DE PIVOXILO DE CEFDITOREN CON UNA SAL DE CASEINA SOLUBLE EN AGUA. ESTA COMPOSICION TIENE REDUCIDO EL SABOR AMARGO DEL PIVOXILO DE CEFDITOREN Y MEJORES PROPIEDADES RESPECTO A LA VELOCIDAD Y CONCENTRACION DE DISOLUCION DEL PIVOXILO DE CEFDITOREN EN AGUA Y A LA PROPORCION DE DISOLUCION DEL PIVOXILO DE CEFDITOREN EN AGUA. ESTA COMPOSICION TAMBIEN PUEDE CONSEGUIR MAS ABSORCION DEL COMPONENTE CEFDITOREN EN EL TUBO DIGESTIVO DESPUES DE LA ADMINISTRACION ORAL. EN ESTA COMPOSICION, LA PROPORCION (POR PESO) DE PIVOXILO DE CEFDITOREN RESPECTO A LA SAL DE CASEINA AÑADIDA PUEDE ESTAR EN EL RANGO DE 1:0,1 A 1:4. AÑADIENDO UNA SAL DE ACIDO FOSFORICO SOLUBLE EN AGUA A LA COMPOSICION, ESTA PUEDE PREVENIR LA DISMINUCION DE LA PROPORCION DE DISOLUCION EN AGUA DEL COMPONENTE PIVOXILO DE CEFDITOREN CUANDO LA COMPOSICION SE GUARDA EN CONDICIONES EXTREMAS.
ES96933635T 1995-10-13 1996-10-14 Composicion antibacteriana para administracion oral. Expired - Lifetime ES2174109T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26584795 1995-10-13

Publications (1)

Publication Number Publication Date
ES2174109T3 true ES2174109T3 (es) 2002-11-01

Family

ID=17422903

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96933635T Expired - Lifetime ES2174109T3 (es) 1995-10-13 1996-10-14 Composicion antibacteriana para administracion oral.

Country Status (15)

Country Link
US (1) US5958915A (es)
EP (1) EP0862915B1 (es)
KR (1) KR100311576B1 (es)
CN (1) CN1102046C (es)
AR (1) AR004014A1 (es)
AT (1) ATE214930T1 (es)
BR (1) BR9610836A (es)
CA (1) CA2234426C (es)
DE (1) DE69620220T2 (es)
ES (1) ES2174109T3 (es)
HU (1) HU224922B1 (es)
MX (1) MX9802849A (es)
PT (1) PT862915E (es)
TW (1) TW458778B (es)
WO (1) WO1997013516A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1051978E (pt) * 1998-01-07 2012-11-20 Meiji Seika Pharma Co Ltd Composições de cefalosporina amorfa cristalograficamente estável e processo para a sua produção
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AU2002224053A1 (en) * 2000-11-21 2002-06-03 Kyorin Pharmaceutical Co. Ltd. Dry syrup preparations
CA2430288C (en) 2000-12-01 2009-03-10 Kyowa Hakko Kogyo Co., Ltd. A composition improved in the solubility or oral absorbability
EP1401402B1 (en) 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
AUPS303202A0 (en) * 2002-06-20 2002-07-11 Pacific Biolink Pty Limited Protein based oral lubricant
EP1555024B1 (en) 2002-10-02 2010-09-29 Meiji Seika Kaisha Ltd. Antibacterial medicinal composition of enhanced oral absorptivity
PT1671635E (pt) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Composição de antibiótico amorfo contendo cefditoreno pivoxil
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
KR101366911B1 (ko) 2004-11-16 2014-02-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 인-함유 표면 처리제를 포함하는 치과용 충전제, 및 그의조성물 및 방법
DE602005023509D1 (de) * 2004-11-16 2010-10-21 3M Innovative Properties Co Dentalfüllstoffe, verfahren, zusammensetzungen mit einem caseinat
DE602005025682D1 (de) 2004-11-16 2011-02-10 3M Innovative Properties Co Dentalfüllstoffe und zusammensetzungen mit phosphatsalzen
EP1811942B1 (en) 2004-11-16 2011-10-05 3M Innovative Properties Company Dental compositions with calcium phosphorus releasing glass
CA2612994A1 (en) 2005-06-08 2006-12-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
WO2010068359A1 (en) 2008-12-11 2010-06-17 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
WO2012010938A2 (en) * 2010-07-23 2012-01-26 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105663058A (zh) * 2016-02-01 2016-06-15 济南康和医药科技有限公司 一种头孢妥仑匹酯纳米粒药物制剂及制备方法
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936609A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS59184122A (ja) * 1983-03-31 1984-10-19 Nitto Electric Ind Co Ltd アクリル系膏体
JPS60102168A (ja) * 1983-11-08 1985-06-06 Tsukishima Shokuhin Kogyo Kk エイコサペンタエン酸強化乳化物及び食品の製造方法
IE58487B1 (en) * 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH0635394B2 (ja) * 1989-02-28 1994-05-11 雪印乳業株式会社 薬物の溶解性および吸収性の改善方法
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤

Also Published As

Publication number Publication date
EP0862915A4 (en) 1998-11-11
EP0862915A1 (en) 1998-09-09
KR100311576B1 (ko) 2001-12-28
HUP9900609A3 (en) 2001-04-28
CA2234426C (en) 2003-07-08
DE69620220D1 (de) 2002-05-02
KR19990064137A (ko) 1999-07-26
ATE214930T1 (de) 2002-04-15
CA2234426A1 (en) 1997-04-17
TW458778B (en) 2001-10-11
US5958915A (en) 1999-09-28
PT862915E (pt) 2002-09-30
BR9610836A (pt) 1999-07-13
AR004014A1 (es) 1998-09-30
MX9802849A (es) 1998-11-30
HU224922B1 (en) 2006-04-28
WO1997013516A1 (en) 1997-04-17
CN1102046C (zh) 2003-02-26
CN1202110A (zh) 1998-12-16
HK1016477A1 (en) 1999-11-05
HUP9900609A2 (hu) 1999-07-28
EP0862915B1 (en) 2002-03-27
DE69620220T2 (de) 2002-11-28

Similar Documents

Publication Publication Date Title
KR930000861B1 (ko) 오메프라졸 직장투여 조성물
UY23373A1 (es) Procedimiento para preparar nuevas composiciones analgesicas
KR900015737A (ko) 배합물
US4164568A (en) Oral scour formulations with citrate
ES2053567T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica de liberacion controlada.
KR960000923A (ko) 단량체성 인슐린 유사체의 제제
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
ES8608875A1 (es) Un metodo para preparar una composicion farmaceutica para aplicacion topica que contiene 1-dodecilazacicloheptan-2-ona.
ES2053123T3 (es) Composicion oral estable de zinc.
MA20050A1 (fr) Nouveaux composes concernant des nouveaux sels d"omeprazole.
MX173433B (es) Composicion acuosa de ibuprofen y procedimiento para su preparacion
BRPI9906372B8 (pt) composição farmaceutica aquosa para aplicação na mucosa
KR880004807A (ko) 수산화알루미늄을 함유하는 이부프로펜 조성물
IL93564A0 (en) Spun fiber comprising pharmaceutical product and its manufacture
ES2100335T3 (es) Derivados de benzopirano y fenol para empleo como agentes inmunoestimulantes.
ES2147744T3 (es) Sistema de administracion cosmetico para acido salicilico y proceso para su preparacion.
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
ES2031467T3 (es) Formulaciones acuosas de esteroides apropiadas para administracion por via nasal.
SI21026B (sl) Stabilen, nasalno, oralno ali sublingvalno uporabljiv farmacevtski pripravek
KR890015745A (ko) 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법
BE901328A (fr) Composition pharmaceutique a absorption reglee.
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 862915

Country of ref document: ES